FDA approves first non-hormone therapy for excessive menstrual bleeding
By APFriday, November 13, 2009
FDA approves new drug for heavy menstrual bleeding
WASHINGTON — Federal health officials have approved a new drug as the first non-hormonal treatment for heavy menstrual bleeding.
The Food and Drug Administration says Lysteda tablets reduce bleeding by acting on a protein that helps blood clot. The drug is made by Newport, Ky.-based Xanodyne Pharmaceuticals.
The main ingredient in the drug was first approved in 1986 as an injection for patients with hemophilia, an inheritable disease that prevents blood clotting.
The FDA warns that taking Lysteda with hormonal contraceptive drugs can increase the risk of blood clots, stroke and heart attacks. Women should only use the products together if there is a strong medical need, the agency says.
Tags: Menstruation, North America, Products And Services, United States, Washington, Women's Health
|
December 10, 2009: 5:21 am
I think it has been long time pending on the table for approval of FDA for this non hormonal therapy for excessive menstrual bleeding. Any way it is good news for all of us. |
|
December 9, 2009: 7:04 am
I think it is good news for the ladies who are suffering from excessive menstrual bleeding. I admit that it is great invention to replace hormone therapy. Thanks for keeping me informed. |
biodentical hormone doctors